PDS Biotechnology Corporation (PDSB)
USD 1.81
(-7.91%)
USD 1.81
(-7.91%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -33.63 Million | -25.7 Million | -12.48 Million | -13.14 Million | -18.07 Million | -33.15 Million |
| Net Income | -42.94 Million | -40.85 Million | -16.91 Million | -14.84 Million | -6.99 Million | -40.86 Million |
| Depreciation & Amortization | 57.32 Thousand | 86.00 | 5357.00 | 15.6 Thousand | 98.41 Thousand | 174.34 Thousand |
| Deferred income taxes | -1.96 Million | - | - | - | -381.51 Thousand | 2.82 Million |
| Stock-based compensation | 7614.32 | 5.19 Million | 4.11 Million | 452.28 Thousand | 3.17 Million | 7.61 Million |
| Change in working capital | -199.27 Thousand | 4.47 Million | 75.81 Thousand | 1.06 Million | -4.6 Million | -3.42 Million |
| Other non-cash items | 3.79 Million | 5.47 Million | 241.03 Thousand | 160.68 Thousand | -9.36 Million | 531.67 Thousand |
| Investing Cash Flow | - | - | - | - | 29.38 Million | - |
| Investments in PPE | -4.00 | - | - | - | - | - |
| Acquisitions | - | - | - | - | 29.1 Million | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | 275 Thousand | - |
| Financing Cash Flow | 16.37 Million | 34.28 Million | 48.88 Million | 29.82 Million | 750 Thousand | -20.26 Million |
| Debt repayment | -59.3 Thousand | -449.32 Thousand | - | - | - | -20.99 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | -270.96 | - | - | - | - |
| Common Stock Issuance | 16.43 Million | 9.85 Million | 48.88 Million | 29.75 Million | 750 Thousand | 1.51 Million |
| Other Financing Activities | 16.43 Thousand | 24.88 Million | 48.88 Thousand | 70.45 Thousand | 750.00 | 721.19 Thousand |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | 5.76 Million | -90.11 Thousand | -105.82 Thousand | 217.5 Thousand | -1.97 Million | -3.96 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | -5.96 Million | 4.56 Million | 181.63 Thousand | 852.16 Thousand | -2.62 Million | 541.19 Thousand |
| Cash at beginning of period | 73.82 Million | 65.24 Million | 28.83 Million | 12.16 Million | 103.69 Thousand | 88.06 Million |
| Cash at end of period | 56.56 Million | 73.82 Million | 65.24 Million | 28.83 Million | 12.16 Million | 34.64 Million |
| Capital Expenditure | -4.00 | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -17.25 Million | 8.57 Million | 36.4 Million | 16.67 Million | 12.05 Million | -53.42 Million |
| Free Cash Flow | -33.63 Million | -25.7 Million | -12.48 Million | -13.14 Million | -18.07 Million | -33.15 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -8.32 Million | -10.6 Million | -10.89 Million | -42.94 Million | -10.84 Million | -11.53 Million |
| Depreciation & Amortization | 15.12 Thousand | 14.4 Thousand | 14.4 Thousand | 57.32 Thousand | 4733.00 | 4736.00 |
| Deferred income taxes | - | - | 232.59 Thousand | -1.96 Million | - | 1.4 Million |
| Stock-based compensation | 1795.72 | 1.63 Million | 1.35 Million | 7.61 Million | 2.07 Million | 2.1 Million |
| Change in working capital | -2.89 Million | -1.24 Million | 400.69 Thousand | -199.27 Thousand | 1.04 Million | 4.16 Million |
| Other non-cash items | 5.12 Million | 2.91 Million | 438.49 Thousand | 3.79 Million | 551.23 Thousand | -957.54 Thousand |
| Investing Cash Flow | -28.99 Thousand | - | - | - | - | - |
| Investments in PPE | -28.99 Thousand | - | - | - | - | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | -13.78 Thousand | 20.01 Million | 10.76 Million | 16.37 Million | 802.32 Thousand | 240 Thousand |
| Debt repayment | -13.78 Thousand | -13.47 Thousand | -13.17 Thousand | -59.3 Thousand | -12.87 Thousand | -12.58 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 20.02 Million | 10.77 Million | 16.43 Million | 815.2 Thousand | 243.74 Thousand |
| Other Financing Activities | - | 20.02 Million | 10.77 Thousand | 16.43 Thousand | 815.20 | 8849.00 |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | -2.74 Million | -981.99 Thousand | 1.61 Million | 5.76 Million | 951.65 Thousand | 2.34 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | -143.29 Thousand | -267.37 Thousand | -1.21 Million | -5.96 Million | 92 Thousand | 1.81 Million |
| Cash at beginning of period | 66.63 Million | 56.56 Million | 54.25 Million | 73.82 Million | 60.62 Million | 65.19 Million |
| Cash at end of period | 57.73 Million | 66.63 Million | 56.56 Million | 56.56 Million | 54.25 Million | 60.62 Million |
| Capital Expenditure | -28.99 Thousand | - | - | - | - | - |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -8.9 Million | 10.07 Million | 2.3 Million | -17.25 Million | -6.37 Million | -4.57 Million |
| Free Cash Flow | -8.88 Million | -9.93 Million | -8.45 Million | -33.63 Million | -7.17 Million | -4.81 Million |
ZEN
4770
2715
CNX
DNOW
LTSK